Development of a Compact Divertor Plasma Simulator for Plasma-Wall Interaction Studies on Neutron-Irradiated Materials

We have developed a compact divertor plasma simulator (CDPS) that can produce steady-state deuterium and/or helium plasmas with densities above ∼ 1018 m−3 for Plasma-Wall Interaction (PWI) studies of neutron-irradiated materials. The maximum particle flux is about 1022 m−2s−1. The CDPS was installed and is being operated in the radiation-controlled area of the International Research Center for Nuclear Materials Science, Institute for Materials Research, Tohoku University. We are able to control sample temperature within uncertainty of 5 °C during plasma exposure by adjusting the cooling air flow rate to the sample holder. The CDPS has a sample-carrier system, which makes it possible to transfer a plasma-irradiated sample from the sample holder to an infrared heater for analysis using thermal desorption spectroscopy (TDS) without exposing it to the air. This avoids the oxidation of the sample and minimizes the time between the end of plasma exposure and TDS analysis. An ITER-like tungsten (W) sample (A.L.M.T. Corp.), which has been irradiated by neutrons to 0.06 dpa in a fission reactor, was exposed to a deuterium plasma in the CDPS. The experimental results clearly show that the total deuterium retention in the neutron-irradiated W sample increases significantly in comparison with a pristine W, as demonstrated by broadening of the TDS spectrum at high temperatures

Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists

Aims/Introduction: We compared clinical characteristics in patients with type 2 diabetes for whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists in Japan. Materials and Methods: Prescription data for 2005, 2008 and 2011 from diabetes specialists' patient registries identified variables related to prescription of different antihyperglycemic agents. Results: A total of 33, 251 prescriptions in 2005, 25, 119 in 2008 and 20, 631 in 2011 were analyzed. Prescribing insulin was related to younger age, long duration of diabetes and glycated hemoglobin (HbA1c) ≥8.0%, but was negatively associated with obesity. Prescribing sulfonylureas was related to older age and long duration of diabetes, but not to obesity. Use of biguanides was related to younger age, short duration of diabetes and obesity, but was negatively associated with HbA1c ≥8.0%. A short duration of diabetes and HbA1c ≥8.0% were associated with use of a DPP-4 inhibitor, but not with obesity. Prescribing GLP-1 receptor agonists was related to younger age, obesity and HbA1c ≥8.0%. Odds ratios for each antihyperglycemic combination therapy were determined based on the characteristics of each included antihyperglycemic agent. Conclusions: These results could be expected to reflect in part the consensus of diabetes specialists, and might provide guidance regarding pharmacotherapy in the clinical setting